

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: Unknown
Gender: Unknown
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Humoral Immunity Panel II

ARUP test code 0050981

Diphtheria Antibody, IgG

0.0 IU/mL

INTERPRETIVE INFORMATION: Diphtheria Ab, IgG

Antibody concentration of greater than 0.1 IU/mL is usually considered protective.

Responder status is determined according to the ratio of a one month post-vaccination sample to pre-vaccination concentrations of Diphtheria IgG Abs as follows:

1. If the one month post-vaccination concentration is less than 1.0 IU/mL, the patient is considered to be a non-responder.
2. If the post-vaccination concentration is greater than or equal to 1.0 IU/mL, a patient with a ratio of less than 1.5 is a non-responder, a ratio of 1.5 to less than 3.0, a weak responder, and a ratio of 3.0 or greater, a good responder.
3. If the pre-vaccination concentration is greater than 1.0 IU/mL, it may be difficult to assess the response based on a ratio alone. A post-vaccination concentration above 2.5 IU/mL in this case is usually adequate.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Tetanus Antibody, IgG

0.0 IU/mL

H=High, L=Low, *=Abnormal, C=Critical

INTERPRETIVE INFORMATION: Tetanus Ab, IgG

Antibody concentration of greater than 0.1 IU/mL is usually considered protective.

Responder status is determined according to the ratio of a one-month post-vaccination sample to pre-vaccination concentration of Tetanus IgG Abs as follows:

1. If the one month post-vaccination concentration is less than 1.0 IU/mL, the patient is considered a non-responder.
2. If the post-vaccination concentration is greater than or equal to 1.0 IU/mL, a patient with a ratio of less than 1.5 is a non-responder, a ratio of 1.5 to less than 3.0, a weak responder, and a ratio of 3.0 or greater, a good responder.
3. If the pre-vaccination concentration is greater than 1.0 IU/mL, it may be difficult to assess the response based on a ratio alone. A post-vaccination concentration above 2.5 IU/mL in this case is usually adequate.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Pn serotype 1 IgG (P13,P20,PNX,V15) 0.10 ug/mL

Pn serotype 3 IgG (P13,P20,PNX,V15) 0.15 ug/mL

Pn serotype 4 IgG (P7,P13,P20,PNX,V15) 0.30 ug/mL

Pn serotype 5 IgG (P13,P20,PNX,V15) 0.32 ug/mL

Pn serotype 6B IgG (P7,P13,P20,PNX,V15) 0.25 ug/mL

Pn serotype 7F IgG (P13,P20,PNX,V15) 0.32 ug/mL

Pn serotype 8 IgG (P20,PNX) 0.23 ug/mL

Pn serotype 9N IgG (PNX) 0.25 ug/mL

Pn serotype 9V IgG (P7,P13,P20,PNX,V15) 0.23 ug/mL

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-290-106563
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 5 | Printed: 11/1/2023 8:31:23 AM
4848

Pn serotype 12F IgG (P20,PNX)	0.24 ug/mL
Pn serotype 14 IgG (P7,P13,P20,PNX,V15)	0.32 ug/mL
Pn serotype 18C IgG (P7,P13,P20,PNX,V15)	0.36 ug/mL
Pn serotype 19F IgG (P7,P13,P20,PNX,V15)	0.35 ug/mL
Pn serotype 23F IgG (P7,P13,P20,PNX,V15)	0.36 ug/mL
Pn Serotype Interpretation	See Note

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-290-106563
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 5 | Printed: 11/1/2023 8:31:23 AM
4848

INTERPRETIVE INFORMATION: Streptococcus pneumoniae Antibodies, IgG

A pre- and postvaccination comparison is required to adequately assess the humoral immune response to the pure polysaccharide Pneumovax 23 (PNX) and/or the protein conjugated Prevnar 7 (P7), Prevnar 13 (P13), Prevnar 20 (P20), and Vaxneuvance (V15) Streptococcus pneumoniae vaccines. Prevacination samples should be collected prior to vaccine administration. Postvaccination samples should be obtained at least 4 weeks after immunization. Testing of postvaccination samples alone will provide only general immune status of the individual to various pneumococcal serotypes.

In the case of pure polysaccharide vaccine, indication of immune system competence is further delineated as an adequate response to at least 50 percent of the serotypes in the vaccine challenge for those 2-5 years of age and to at least 70 percent of the serotypes in the vaccine challenge for those 6-65 years of age. Individual immune response may vary based on age, past exposure, immunocompetence, and pneumococcal serotype.

Responder Status	Antibody Ratio
Nonresponder	Less than twofold increase and postvaccination concentration less than 1.3 ug/mL
Good responder	At least a twofold increase and/or a postvaccination concentration greater than or equal to 1.3 ug/mL

A response to 50-70 percent or more of the serotypes in the vaccine challenge is considered a normal humoral response. (Daly, 2014) Antibody concentration greater than 1.0-1.3 ug/mL is generally considered long-term protection. (Daly, 2015)

References:

1. Daly TM, Pickering JW, Zhang X, et al. Multilaboratory assessment of threshold versus fold-change algorithms for minimizing analytical variability in multiplexed pneumococcal IgG measurements. Clin Vaccine Immunol. 2014;21(7):982-988.
2. Daly TM, Hill HR. Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function. Clin Vaccine Immunol. 2015;22(2):148-152.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Diphtheria Antibody, IgG	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tetanus Antibody, IgG	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 1 IgG (P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 3 IgG (P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 4 IgG (P7,P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 5 IgG (P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 6B IgG (P7,P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 7F IgG (P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 8 IgG (P20,PNX)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 9N IgG (PNX)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 9V IgG (P7,P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 12F IgG (P20,PNX)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 14 IgG (P7,P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 18C IgG (P7,P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 19F IgG (P7,P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn serotype 23F IgG (P7,P13,P20,PNX,V15)	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pn Serotype Interpretation	23-290-106563	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-290-106563
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 5 of 5 | Printed: 11/1/2023 8:31:23 AM
4848